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Cutaneous infectionThe empirical therapy of community-acquired pneumonia (CAP) and complicated skin and soft tissue infections
(cSSTIs)must be based onupdated bacterial distribution and susceptibility data. A nationwide study consecutive-
ly collected 1288 isolates from CAP (n= 467) and cSSTIs (n= 821) from 18 French hospitals between 2012 and
2013. The MIC values of commonly used antimicrobial agents, including ceftaroline, were determined. Bacterial
distribution featured Pneumococcus, Haemophilus inﬂuenzae, and Staphylococcus aureus for CAPs and
S. aureus, β-hemolytic streptococci and Enterobacteriaceae for cSSTIs. Antimicrobial susceptibility testing
indicated i) the sustained third-generation cephalosporins and levoﬂoxacin activity against pneumococci
and H. inﬂuenzae, ii) no methicillin-resistant Staphylococcus aureus emergence among respiratory pathogens,
iii) the high in vitro activity of ceftaroline against staphylococci from cSSTIs (98.7% susceptibility), and iv)
the worrisome decreasing ﬂuoroquinolone and third-generation cephalosporin susceptibilities among
Enterobacteriaceae. This laboratory-based survey depicts a contrasting situation and supports the scoring of
patients for the resistant pathogen risk before empirical therapy.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Among the global burden of infectious diseases, the lower respirato-
ry tract (LRTIs) and skin and skin structure infections rank at the top in
terms of mortality and morbidity. In 2010, LRTIs belonged to the top 10
diseases responsible for premature deaths in the United States (Murray
and Lopez, 2013). In accordance with the World Health Organization,
LRTIs cause 3.5 million deaths yearly worldwide, ranked as the ﬁrst
common infectious cause and the third overall cause of death
(Wunderink and Waterer, 2014). The yearly number of skin structure
infections in the United States has reached 15 million cases, leading to
870,000 hospitalizations (Chambers, 2014). Next to common superﬁcial+33-1-49-81-28-39.
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. This is an open access article undertissue infections, complicated skin and soft tissue infections (cSSTIs)
constitute a heterogeneous group of severe disorders leading to disabi-
lity or death if not adequately managed (Dryden, 2010). Furthermore,
the emergence of community-acquired (CA), methicillin-resistant
Staphylococcus aureus (MRSA) has dramatically modiﬁed the epidemi-
ology and management of these groups of infections in the United
States; CA MRSA constitutes now a serious threat for European
healthcare authorities (Köck et al., 2010). Prompt and accurate antimi-
crobial chemotherapy of these infections is necessary—but sometimes
not sufﬁcient—to prevent a poor outcome; empirical therapy is based
on the knowledge of microbial distribution and corresponding antimi-
crobial susceptibilities (Dellit et al., 2007; Jenkins et al., 2014). Facing
the spread of antibiotic-resistant pathogens, the choice of antibacterial
compound should balance its individual and collective impact. Overuse
of extended-spectrum agents could be detrimental in increasing drug-
associated adverse effects, Clostridium difﬁcile infection risk, and selec-
tion of multidrug-resistant (MDR) pathogens. Updated nationwide
data are needed to overcome temporal and geographical variations
(Wunderink and Waterer, 2014). We reported the results of a national
multicenter study focusing on community-acquired pneumonia (CAP)
and cSSTIs i) to determine the distribution of pathogens and ii) to test
their in vitro antimicrobial susceptibility including referent and
new compounds.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Paris (n = 2) and the surrounding  
















Fig. 1. Geographical location of the participating laboratories (n = 18).
176 C. Leprince et al. / Diagnostic Microbiology and Infectious Disease 83 (2015) 175–1822. Materials and methods
The French PREMIUMstudy is a laboratory-based, nationwide obser-
vational study involving 18 hospital centers equally distributed geo-
graphically in France and including teaching (n = 15) and
nonteaching (n = 3) hospitals. The location of each participant is re-
ported in Fig. 1. The inclusion of strains was conducted prospectively
from February 1, 2012, to June 1, 2013. Each center collected a
predeﬁned number of consecutive isolates cultured from patients with
CAP (n = 30) or cSSTIs (n = 50), excluding obligate anaerobes.2.1. Inclusion criteria
The CAP pathogens should be obtained from clinical samples from
adult patients, aged ≥18 years, with CAP. The diagnosis of hospital- or
healthcare-associated pneumonia (HCAP) was considered an exclusion
criterion. Only 1 isolate per patient was included, collected from the
sputum, bronchoscopic lavage (BAL), tracheal/bronchial aspirate, bron-
choscopic protected brush specimen, blood culture, or pleural ﬂuid.
The cSSTI pathogens should be obtained from clinical samples from
adult patients aged ≥18 years with the diagnosis of cellulitis,
abscess, signiﬁcant surgical site infection, wound infection (included
orthopedic-related infections), deeper soft tissue infection, infectedhuman or animal bite, or necrotizing infection. The diagnosis of uncom-
plicated skin and soft tissue infection (SSTI) as impetigo, erysipelas,
small abscess, or boils was considered an exclusion criterion. Isolates
from invasive sampling were preferred, including ﬁne needle aspira-
tion; punction/biopsy; perioperative sample; or, by default, good-
quality swabs (i.e., swabbing of deep tissues after wound debridement).
Strains from CA and healthcare-associated (including hospital) infections
were accepted.2.2. Identiﬁcation and antimicrobial susceptibility testing
The microorganisms were identiﬁed at the participating institutions
by local routinemethodology and sent to a core laboratory (Department
of Microbiology, CRETEIL). Brieﬂy, the participating laboratories
identiﬁed bacterial species using matrix-assisted laser desorption/
ionization-time-of-ﬂightmass spectrometry and additional biochemical
tests (e.g., the optochin susceptibility of Streptococcus pneumoniae). In
the case of discordance between the antimicrobial susceptibility
results (see below) and bacterial identiﬁcation, the core laboratory
veriﬁed the species determination using referencemethods as RNA16s se-
quencing. The core laboratory determined the MICs of the antibiotics
by the broth microdilution method (Sensititre® panels; TREK Diag-
nostic Systems, Cleveland, OH, USA) according to EUCAST guidelines
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icillin, amoxicillin, cefotaxime, ceftaroline, erythromycin, clindamycin,
gentamicin, levoﬂoxacin, vancomycin, teicoplanin, linezolid, daptomycin,
and tigecycline for Gram-positive bacteria and amoxicillin, amoxicillin
plus clavulanic acid, cefotaxime, ceftaroline, ertapenem, piperacillin plus
tazobactam, gentamicin, amikacin, levoﬂoxacin, and tigecycline for
Gram-negative bacteria. A calcium supplement (50mg/L ﬁnal concentra-
tion)was used for testing daptomycin. Among staphylococci, methicillin
resistancewas detected using the cefoxitin test at 4mg/L concentration.
For the third-generation cephalosporin–nonsusceptible Enterobacteria-
ceae, the double disk synergy test was performed to detect extended-
spectrum β-lactamase (ESBL) according to EUCAST recommendations
(http://www.eucast.org/resistance_mechanisms). Control strains were
tested in every set of tests (see the quality control strategy section). Sus-
ceptibility results were interpreted in accordance with EUCAST 2013
breakpoints (http://www.eucast.org/clinical_breakpoints).
2.3. Quality control strategy
A panel of 6 control strains was tested for identiﬁcation and antimi-
crobial susceptibility at the beginning and end of the inclusion period by
each participating center: Escherichia coli ATCC 25922, S. aureus ATCC
29213, S. pneumoniae ATCC 49619, Haemophilus inﬂuenzae ATCC
49247, Enterococcus faecalis ATCC 29212, and Pseudomonas aeruginosa
ATCC 27853. Targeted acceptable ranges were provided by EUCAST
(http://www.eucast.org/antimicrobial_susceptibility_testing/
qc_tables) and CLSI for the ceftaroline susceptibility of E. faecalis.
Concerning P. aeruginosa that is naturally resistant to ceftaroline, the
target MIC (±1 log2 dilution) was determined by the core laboratory.
3. Results and discussion
Evidence-based practice guidelines should be based on epidemio-
logical data concerning the distribution and antimicrobial susceptibili-
ties of the different pathogens in a particular clinical setting (Dellit
et al., 2007). Unfortunately, such accurate data are sparse for CAPs and
cSSTIs: European guidelines recommend that the primary care physi-
cian should not performmicrobiological testing when LRTI is suspected
(Eccles et al., 2014;Woodhead et al., 2011). Considering the large yearly
epidemiological survey based on bloodstream isolates without a known
cause of sepsis (e.g., the European Center for Diseases Prevention and
Control survey, http://www.ecdc.europa.eu/en/activities/surveillance/
Pages/index.aspx), additional studies focusing on speciﬁc clinical pre-
sentation are then required. In the present study, we provided
hospital- and laboratory-based nationwide data concerning the distri-
bution and antibiotic susceptibility of bacteria from CAP and cSSTIs.
3.1. The studied bacterial population
The 18 participating centers included 1288 strains, 467 strains from
CAP and 821 from cSSTIs. Participating laboratories from teaching and
nonteaching hospitals equally geographically distributed provided a
representative sample of bacterial isolates from these 2 clinical entities.
Moreover, the large period of our study and predeﬁned number of
strains to include eliminated the risk of bias due to seasonal variation
or a center effect. Demographic data from patients were not collected
for legal reasons: the lack of stratiﬁed data according to age, comorbid-
ity, or wards of admission was clearly a limitation of our study that was
focused on strains rather than on patients. Additional studies focused on
clinically deﬁned subgroups are required.
3.2. Quality control performances
The global accuracy of the quality control results was above 90% for
all of the participants.3.3. Bacterial etiologies of CAP
The sample types were sputum (36%), tracheobronchial aspirate
(27%), BAL (18%), blood culture (16%), and pleural ﬂuid (3%). The distri-
bution of the respiratory pathogens is reported in Table 1A, featuring
S. pneumoniae (n = 213, 45.5%), H. inﬂuenzae (n = 71, 15.2%),
S. aureus (n = 59, 12.6%), Enterobacteriaceae (n = 57, 12.2%), and
Branhamella catarrhalis (n = 21, 4.5%). In the European REACH study
that included 582 microbiologically documented CAPs from 10 coun-
tries between 2010 and 2011, Enterobacteriaceae and P. aeruginosa
ranked second and fourth, respectively; MRSA were predominant
among S. aureus, the third pathogen responsible for CAPs (Blasi et al.,
2013). In a recent European review, P. aeruginosa represented up to
16.8% of pathogens responsible for PAC among 10 studies (Torres
et al., 2014). MDR pathogens such as P. aeruginosa or MRSA are more
frequently identiﬁed from HCAP than CAPs (Shorr et al., 2008). The dis-
tinction between HCAPs and CAPs is quite tricky, requiring extensive,
time-consuming investigations to evaluate the patient's history of anti-
biotics use during the previous 90 days or a family member with aMDR
pathogen (Wunderink andWaterer, 2014). To a large extent, previously
published epidemiological studies did not surmount this bias that
added i) to the difﬁculty to diagnose CAP in patients with underlying
cardiopulmonary disease and ii) to the poor quality of some microbio-
logical specimens (Wunderink andWaterer, 2014). Such ﬂaws increase
the inclusion of colonizing bacteria rather than strictly pathogenic ones.
Colonizing pathogens, being more resistant to antibiotics, could artiﬁ-
cially corrupt the resistance prevalence. Obviously, our studydid not en-
tirely overcome these pitfalls; we tried to anticipate and moderate the
inclusion of isolates from healthcare-associated, nonpneumonia LRTIs
in underlining these biases in the inclusion criteria and in supporting
the protected and/or directed specimens. However, in the present
work, one-third of the respiratory specimenswere from sputum: exam-
ination and culture of a sputum specimen is yet a valuable approach to
identify a respiratory pathogen (Woodhead et al. 2011). Furthermore, in
the recent review from Torres et al. (2014), 91% (20/22) of the reported
studies included bacteria from sputum. We did not explore the role of
intracellular bacteria such as Mycoplasma pneumoniae, Legionella spp.,
or Chlamydophila pneumoniae. Although putatively responsible for a
signiﬁcant part of the CAPs, the real contribution of these pathogens is
blurred by the heterogeneity of the available diagnostic methods, in-
cluding serology, nuclear acid ampliﬁcation test, antigen detection,
and speciﬁc culture (Woodhead et al., 2011).
3.4. Antimicrobial susceptibilities of respiratory pathogens
Antimicrobial susceptibilities are reported in Table 2. Of the 210 tes-
ted S. pneumoniae, 38.1% showed a reduced susceptibility to penicillin
(MIC N0.06 mg/L). Considering H. inﬂuenzae, 18.6% of the strains were
resistant to amoxicillin. MRSA strains represented 12% of S. aureus;
all but 1 were susceptible to ceftaroline. The resistance to third-
generation cephalosporins reached 14% of the 57 Enterobacteriaceae,
regardless of the underlying mechanism. Among the resistant strains,
no E. coli was identiﬁed, and 3 of 9 other Enterobacteriaceae were
ESBL producers. In addition to the previously reported limits of the pre-
sent study, genotypic characterization of the third-generation cephalo-
sporin resistance mechanisms should be performed; nevertheless, the
clinical success of the antimicrobial chemotherapy is mainly supported
by the MIC values rather than the underlying resistance mechanism.
The analysis of antimicrobial resistancepatterns among themain patho-
gens has led to different interesting ﬁndings. First, although the percen-
tage of penicillin non susceptible pneumococci was high (38%),
comparing with the value reported from French bloodstream isolates
(22.4%; 2013 ECDC data, 2013, http://www.ecdc.europa.eu) or from
European respiratory tract specimens (17.9%), no strain was highly re-
sistant to amoxicillin, cefotaxime, or ceftaroline (Farrell et al., 2013).
This comforting statement should be carefully monitored: in the
Table 1
Distribution of the 1288 strains according to clinical origin.
Bacteria n (%)
A. Respiratory pathogens (n = 467)
Gram-positive bacteria 292 (62.5)
Staphylococcus spp. 65 (13.9)
S. aureus 59 (12.6)
Coagulase-negative staphylococci 6 (1.3)
Streptococcus spp. 222 (47.5)
S. pneumoniae 213 (45.5)
Streptococcus pyogenes (group A Streptococcus) 5 (1.1)
Other Streptococcus spp. 4 (0.9)
Gram-positive bacilli 5 (1.1)
Corynebacterium spp. 3 (0.6)
Actinomyces spp. 2 (0.4)
Gram-negative bacteria 175 (37.5)
Non-Enterobacteriaceae Gram-negative bacteria 118 (25.3)
Branhamella catarrhalis 21 (4.5)
H. inﬂuenzae 71 (15.2)
Other Haemophilus spp. 5 (1.1)
Pasteurella spp. 1 (0.2)
Bordetella bronchiseptica 1 (0.2)
P. aeruginosa 16 (3.4)
Other non-Enterobacteriaceae 3 (0.6)
Enterobacteriaceae 57 (12.2)
E. coli 20 (4.3)
Klebsiella oxytoca 7 (1.5)
Klebsiella pneumoniae 9 (1.9)
Enterobacter aerogenes 4 (0.9)
Enterobacter cloacae 3 (0.6)
Citrobacter freundii 2 (0.4)
Citrobacter koseri 1 (0.2)
Proteus mirabilis 3 (0.6)
Serratia marcescens 3 (0.6)
Other Enterobacteriaceae 5 (1.1)
Total 467 (100)
B. Pathogens from cSSTIs (n = 821)
Gram-positive bacteria 525 (63.9)
Staphylococcus spp. 386 (47.0)
S. aureus 333 (40.6)
Staphylococcus epidermidis 23 (2.8)
Staphylococcus lugdunensis 14 (1.7)
Other coagulase-negative staphylococci 16 (1.9)
Streptococcus spp. 98 (11.9)
S. pneumoniae 3 (0.4)
S. pyogenes (group A Streptococcus) 34 (4.1)
Streptococcus agalactiae (group B Streptococcus) 25 (3.0)
Streptococcus dysgalactiae (group G Streptococcus) 13 (1.6)
Streptococcus constellatus 11 (1.3)
Other Streptococcus spp. 12 (1.5)
Enterococcus spp. 34 (4.1)
E. faecalis 23 (2.8)
Enterococcus faecium 6 (0.7)
Other Enterococcus spp. 5 (0.6)
Gram-positive bacilli 7 (0.8)
Corynebacterium spp. 4 (0.5)
Bacillus spp. 2 (0.2)
Nocardia spp. 1 (0.1)
Gram-negative bacteria 296 (36.1)
Non-Enterobacteriaceae Gram-negative bacteria 55 (6.7)
Branhamella catarrhalis 1 (0.1)
H. inﬂuenzae 2 (0.2)
Eikenella corrodens 4 (0.5)
Pasteurella spp. 14 (1.7)
P. aeruginosa 33 (4)
Other non-Enterobacteriaceae 3 (0.4)
Enterobacteriaceae 239 (29.1)
E. coli 89 (10.8)
K. oxytoca 8 (1.0)
K. pneumoniae 17 (2.1)
E. aerogenes 7 (0.9)
E. cloacae 36 (4.4)
C. freundii 6 (0.7)
C. koseri 8 (1.0)
M. morganii 12 (1.5)
P. mirabilis 33 (4.0)
S. marcescens 10 (1.2)
Other Enterobacteriaceae 13 (1.6)
Total 821 (100)
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S. pneumoniae (n = 210)
Amoxicillin 0.25 1 0.25–2 78.6
Cefotaxime 0.03 1 0.008–2 89.5
Ceftaroline 0.008 0.12 0.008–0.5 99.5
Erythromycin 0.12 32 0.12–32 72.4
Clindamycin 0.12 8 0.12–8 79
Levoﬂoxacin 1 1 0.12–2 100
Linezolid 1 2 0.25–2 100
Teicoplanin 0.06 0.12 0.06–0.5 100
Vancomycin 0.5 0.5 0.12–1 100
Penicillin-nonsusceptible
S. pneumoniae (n = 80)
Amoxicillin 1 2 0.25–2 45.0
Cefotaxime 0.5 1 0.008–2 72.5
Ceftaroline 0.06 0.12 0.008–0.5 98.7
Erythromycin 0.25 8 0.12–8 56.2
Clindamycin 8 32 0.12–32 45.0
Levoﬂoxacin 1 1 0.12–2 100
Linezolid 2 2 0.25–2 100
Teicoplanin 0.06 0.25 0.06–0.5 100
Vancomycin 0.5 0.5 0.12–1 100
Staphylococcus aureus (n = 59,
including 7 MRSA*)
Ceftaroline 0.25 0.5 0.015–2 98.3
Erythromycin 0.25 32 0.25–32 76.3
Clindamycin 0.12 2 0.12–8 89.8
Gentamicin 0.25 0.5 0.12–1 100
Tigecycline 0.12 0.12 0.06–0.12 100
Levoﬂoxacin 0.12 8 0.12–32 88.1
Linezolid 2 2 0.5–2 100
Daptomycin 0.5 1 0.25–1 100
Teicoplanin 0.5 1 0.25–2 100
Vancomycin 1 2 0.5–2 100
H. inﬂuenzae (n = 70)
Amoxicillin 0.5 128 0.12–128 81.4
Amoxicillin plus clavulanic acid 0.5 1 0.12–4 98.6
Cefotaxime 0.015 0.06 0.015–0.12 100
Ceftaroline 0.015 0.03 0.015–0.25 90
Ertapenem 0.03 0.06 0.03–0.25 100
Levoﬂoxacin 0.015 0.03 0.015–0.5 100
Enterobacteriaceae (n = 57)
Cefotaxime 0.03 16 0.016–32 86.0
Ceftaroline 0.25 16 0.015–32 75.4
Piperacillin -tazobactam 2 64 0.12–128 82.5
Ertapenem 0.03 0.25 0.03–1 98.2
Gentamicin 1 2 0.25–256 94.7
Amikacin 4 8 1–8 100
Levoﬂoxacin 0.06 0.5 0.015–8 93.0
*: Methicillin resistant Staphylococcus aureus.
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generation cephalosporins have been reported (Mendes et al., 2014). In
the work of Mendes et al. (2014), ceftaroline in vitro activity was fortu-
nately conserved; the MIC50 and MIC90 values of this new compound
were 0.008 and 0.12 mg/L, respectively, in our samples of strains. Con-
sidering macrolides, the percentage of nonsusceptible strains (27.6%)
was as high as that in the bacteremia-based ECDC (28.9%) and
European respiratory tract-based (26.7%) reports (Farrell et al., 2013;
http://www.ecdc.europa.eu). No S. pneumoniae was highly resistant to
levoﬂoxacin: although rare in Europe, the lack of emerging ﬂuoroquin-
olone resistance among this recent respiratory sample of pneumococci
constitutes quite reassuring data (Farrell et al., 2013). The second im-
portant ﬁnding was the low proportion of MRSA, most of them being
ﬂuoroquinolone resistant (6/7), a characteristic of hospital-acquired
clones, and ceftaroline susceptible (6/7). Beyond antibiotic-resistant
patterns, their genetic background and toxin carriage determination
(including Panton-Valentine leukocidin) should be of interest. Thus
far, CA MRSA did not emerge in France among CAP pathogens.3.5. Bacterial etiologies of cSSTIs
The main sample types were perioperative samples (44%), good-
quality swabs (33%), and ﬁne and needle aspiration punction/biopsy
(22%). Considering the origin of the infection, the CA/nosocomial ratio
was balanced (51.1% versus 48.9%). The distribution of bacteria isolated
from cSSTIs is reported in Table 1B. S. aureus was the most frequently
identiﬁed pathogen (n = 333, 40.6%), followed by members of the En-
terobacteriaceae family (n = 239, 29.1%) and β-hemolytic streptococci
(groups A and B, n = 59, 7.1%).
Considering the large variety of clinical entities included in the SSTI
domain, each study should be carefully analyzed to extract usable data
in a clinical setting. Our work focused on cSSTIs diagnosed at the hospi-
tal setting. Invasive specimens such as needle aspiration or periopera-
tive samples provided more than two-thirds of the strains, attesting to
their clinical relevance. In the present study, bloodstream isolates
were excluded; in thework ofGarau et al. (2013), bacteremiawaspresent
in only 6.3% of cSSTI episodes. Gram-positive bacteria dominated the
pathogen distribution, featuring S. aureus as expected. Unlike in some
previously published European data, the β-hemolytic streptococci over-
took enterococci (Garau et al., 2013; Moet et al., 2007). This could be
explained by the case mix of the study and, particularly, the proportion
of nosocomial cSSTIs: indeed, enterococci are more frequent when
infections originated from a hospital (Zilberberg et al., 2009). The same
explanation could be mentioned for the low ranking of P. aeruginosa.
According to the protocol of the study, anaerobic bacteria were excluded:
additional studies dealing with technical hurdles are required to explore
their contribution to cSSTIs.
3.6. Antimicrobial susceptibilities of skin and skin structure pathogens
Antimicrobial susceptibilities are reported in Table 3. Of the 332 via-
ble S. aureus, 20.2%wereMRSA, and 2 of 67were resistant to ceftaroline.
Methicillin resistance was characterized among 20% of S. aureus: this
percentage corresponded to the 19.2% value reported by the ECDC for
bacteremic isolates (http://www.ecdc.europa.eu). As reported in a na-
tional prospective study performed in 2006 concerning CA SSTIs in
France, resistance to ﬂuoroquinolones was identiﬁed among three-
quarters of MRSA isolates: this supported our previous ﬁnding based
on genetic background (agr typing) and toxin screening that CA MRSA
has not spread in France (Lamy et al., 2012). However, the genetic cha-
racterization of MRSA is required: after our ﬁrst description of an
intrafamilial autochthonous cluster due to USA300 in 2008 (Traore
et al., 2014), an outbreak was reported in 2011–2012 (Baud et al.,
2014). TheMIC90 of themajor anti-MRSA compounds was 1mg/L (van-
comycin, teicoplanin, daptomycin, and ceftaroline), except for linezolid
(2mg/L); only 2 strains exhibited a ceftaroline of MIC of 2mg/L. In vitro
selection of ceftaroline-resistant isolates among Gram-positive bacteria
is difﬁcult to obtain (Clark et al., 2011). Nevertheless, in 2008 and 2010,
the ﬁrst large international studies regarding ceftaroline susceptibility
performed before its marketing led to the identiﬁcation of ceftaroline-
resistant MRSA (Alm et al., 2014; Jones et al., 2010). Resistance to
ceftaroline was associated with mutations in penicillin-binding protein
2a; strainswith anMIC value of 2mg/L had a Glu239Lysmutation in the
non–penicillin-binding domain, while those with a higher MIC value
had an additional mutation in the penicillin-binding domain (Alm
et al., 2014). We did not identify isolates with a higher MIC (N2 mg/L).
In the present work, the frequency of the strains seemed to be lower
than that in these retrospective studies: 3% (2/391) versus 4.6% (124/
2700) (Jones et al., 2010). As recently suggested by postapproval studies,
ceftaroline could be of interest to treat patients with invasive MRSA
infections resistant to a ﬁrst-line agent (Stryjewski et al., 2015).
Regarding coagulase-negative staphylococci (CNS), MIC90 values
equivalent to the clinical breakpoint were listed for vancomycin and
daptomycin; resistance to teicoplanin was identiﬁed for 43.4% of the
isolates. The in vitro activity of ceftaroline against CNS seems to be
Table 3
Antimicrobial susceptibility of the main bacterial species isolated from cSSTIs according to EUCAST breakpoints.
Antimicrobial agent (no. of viable strains) MIC50 (mg/L) MIC90 (mg/L) MIC range (mg/L) % Susceptibility
S. aureus (n = 332)
Ceftaroline 0.25 0.5 0.06–2 99.4
Erythromycin 0.25 32 0.25–32 74.5
Clindamycin 0.06 0.25 0.06–8 91.3
Gentamicin 0.25 0.5 0.06–8 98.8
Tigecycline 0.06 0.12 0.06–0.25 100
Levoﬂoxacin 0.25 8 0.06–32 81.7
Linezolid 2 2 0.5–4 100
Daptomycin 0.5 1 0.25–1 100
Teicoplanin 0.5 1 0.25–2 100
Vancomycin 1 1 0.5–2 100
MRSA (n = 67)
Ceftaroline 0.5 1 0.12–2 97.0
Erythromycin 0.5 32 0.25–32 59.7
Clindamycin 0.06 8 0.06–8 70.1
Gentamicin 0.25 1 0.06–8 95.5
Tigecycline 0.12 0.12 0.03–0.12 100
Levoﬂoxacin 8 16 0.06–32 23.9
Linezolid 2 2 0.25–2 100
Daptomycin 0.5 1 0.06–1 100
Teicoplanin 0.5 1 0.12–1 100
Vancomycin 1 1 0.25–1 100
Coagulase-negative staphylococci (n = 53)
Ceftaroline 0.25 1 0.015–4 94.3
Erythromycin 0.25 32 0.12–32 58.5
Clindamycin 0.12 8 0.12–8 77.4
Gentamicin 0.25 8 0.12–8 69.8
Tigecycline 0.06 0.25 0.03–0.25 100
Levoﬂoxacin 0.25 8 0.12–32 67.9
Linezolid 1 1 0.25–2 100
Daptomycin 0.5 1 0.06–1 100
Teicoplanin 1 8 0.12–8 56.6
Vancomycin 1 2 0.5–2 100
Group A or B streptococci (n = 59)
Penicillin 0.015 0.06 0.015–0.12 100
Amoxicillin 0.25 0.25 0.25–0.25 ND
Cefotaxime 0.03 0.06 0.008–0.12 ND
Ceftaroline 0.008 0.03 0.008–0.25 ND
Erythromycin 0.12 16 0.12–32 69.5
Clindamycin 0.12 1 0.12–8 86.4
Tigecycline 0.03 0.06 0.03–0.25 100
Levoﬂoxacin 1 1 0.12–1 100
Linezolid 1 1 0.25–2 100
Daptomycin 0.25 0.5 0.12–1 100
Teicoplanin 0.12 0.5 0.06–1 100
Vancomycin 0.5 1 0.12–1 100
Other streptococci (n = 37)
Penicillin 0.03 1 0.015–8 83.8
Amoxicillin 0.25 1 0.25–4 86.5
Cefotaxime 0.06 2 0.008–8 86.5
Ceftaroline 0.015 0.25 0.008–0.5 ND
Erythromycin 0.12 32 0.12–32 ND
Clindamycin 0.12 8 0.12–8 75.7
Tigecycline 0.03 0.25 0.03–1 ND
Levoﬂoxacin 1 2 0.12–2 ND
Linezolid 1 2 0.25–2 ND
Daptomycin 0.25 1 0.12–2 ND
Teicoplanin 0.12 0.5 0.06–0.5 100
Vancomycin 0.5 1 0.12–1 100
E. coli (n = 89)
Amoxicillin 128 128 1–128 40.5
Amoxicillin plus clavulanic acid 8 32 1–128 62.9
Cefotaxime 0.06 16 0.03–32 85.4
Ceftaroline 0.25 32 0.015–32 73.0
Piperacillin –tazobactam 2 32 0.12–128 82
Ertapenem 0.03 0.06 0.03–0.5 100
Gentamicin 1 2 0.5–128 93.3
Amikacin 4 8 1–16 98.9
Levoﬂoxacin 0.06 8 0.015–64 83.1
Tigecycline 0.12 0.25 0.12–1 100
Other Enterobacteriaceae (n = 150)
Cefotaxime 0.06 32 0.015–32 81.3
Ceftaroline 0.25 32 0.015–32 68.7
Piperacillin –tazobactam 1 128 0.12–128 79.3
Ertapenem 0.03 0.25 0.03–2 98.0
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Table 3 (continued)
Antimicrobial agent (no. of viable strains) MIC50 (mg/L) MIC90 (mg/L) MIC range (mg/L) % Susceptibility
Gentamicin 0.5 32 0.25–256 88.0
Amikacin 2 8 1–32 96.0
Levoﬂoxacin 0.06 2 0.015–64 87.3
ND = not determined owing to the lack of ofﬁcial breakpoint.
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susceptibility decreased (MIC90= 2 and 8mg/L, respectively). Regarding
MRSA, the putative contribution of ceftaroline to the therapy ofMDR CNS
infection should be further investigated.
While β-hemolytic streptococci were fully susceptible tomost of the
tested antibiotics except macrolides, the resistance to third-generation
cephalosporins reached 14.6% of the 89 E. coli and 18.7% for the other
Enterobacteriaceae, regardless of the underlying mechanism. Among
the resistant strains, the proportion of the ESBL producer was 69% for
E. coli (9 of 13) and 61% for the other Enterobacteriaceae (17 of 28). Flu-
oroquinolone resistance was identiﬁed among 16.9% and 12.7% of the
strains, respectively. These patterns of susceptibility underlined the
worldwide spread of ﬂuoroquinolones and third-generation cephalo-
sporin resistance among enterobacteria. We cannot exclude that a
part of the ﬂuoroquinolone and/or third-generation cephalosporin-
resistant strains were identiﬁed within the context of healthcare-
associated infection. However, in France, such strains were increasingly
reported from asymptomatic carriers in the community (Birgy et al.,
2012; Nicolas-Chanoine et al., 2013). This rate of cefotaxime resistance
exceeds the value reported by the ECDC for bacteremia (10% for
E. coli) but is concordant with those reported in European studies fo-
cused on SSTIs (28.2%) (http://www.ecdc.europa.eu, Farrell et al.,
2013). Considering the signiﬁcant proportion of ﬂuoroquinolone-
resistant isolates (17%), only ertapenem and amikacin exhibited a sus-
ceptibility rate higher than 90%. In this context, the ceftaroline plus
avibactam combination seems to be a promising alternative to carba-
penem (Flamm et al. 2014).
4. Conclusion
In the current period of increasing the scarcity of new antimicrobial
compounds, empirical therapy should be focused on a narrow set of
targeted bacteria, including the probability of acquired resistance. We
provided accurate nationwide data concerning 2 of the most frequent
infectious diseases diagnosed at the hospital. This laboratory-based
studyupdates the respective spectrumof themain antimicrobial agents,
including ceftaroline fosamil, a new cephalosporin with retained activi-
ty against MRSA and penicillin-non-susceptible pneumococci. This
snapshot depicted a contrasting situation for CAP and SSTIs: the
reassuring evolution of staphylococcal and pneumococcal β-lactamin
susceptibility was balanced by the worrisome trend of cephalosporin
and ﬂuoroquinolone resistance among Enterobacteriaceae. Although
limited by the lack of stratiﬁcation to clinical characteristics and proba-
bly not considering the biases associated with the partial misidentiﬁca-
tion of the nature and origin of the clinical presentations, this work
contributes to the knowledge of the moving landscape of CAP and
SSTIs. Given the extent of decreasing antibiotic susceptibility of the
primary involved bacteria, this work underlines the need for scoring
patients for the risk of resistant pathogens to preserve the efﬁcacy of
the remaining active antimicrobial compounds.
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